A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to oral cyclosporine A, or when this treatment is not medically advisable

Trial Profile

A phase 3 study investigating the efficacy, safety, and tolerability of Dupilumab administered to adult patients with severe atopic dermatitis who are not adequately controlled with or are intolerant to oral cyclosporine A, or when this treatment is not medically advisable

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms CAFE; LIBERTY AD CAFE
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 28 Nov 2017 Primary endpoint [Proportion of patients with Eczema Area and Severity Index (EASI) 75 (75% improvement from baseline) at week 16] has been met, according to the results published in the British Journal of Dermatology.
    • 28 Nov 2017 Results published in the British Journal of Dermatology
    • 08 Nov 2017 According to a Regeneron Pharmaceuticals media release, Regeneron Pharmaceuticals and Sanofi presented positive results from this study at the annual European Academy of Dermatology and Venereology (EADV) Congress in Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top